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In several forms of human cancer, only a phenotypic subset of cancer cells, usually termed ‘‘cancer
stem cells’’ (CSC), can initiate tumor growth when transplanted. In this issue of Cell Stem Cell,
Hermann et al. (2007) analyze the relationship between CSC and tumor metastasis.Tumor tissues have long been known
to be composed of heterogeneous
populations of cancer cells. Recently,
a new wave of studies has begun to
address whether distinct cancer cell
subpopulations purified from the
same solid tumor tissue are character-
ized by distinct functional properties.
Remarkably, these studies have
shown that, in several types of human
cancer, only a phenotypic subset of
cancer cells, usually a minority subset,
is endowed with tumorigenic capacity,
i.e., is capable to sustain the growth
of a new tumor when injected in im-
munodeficient mice. This tumorigenic
subset of cells is characterized by
three main properties: (1) it expresses
a distinctive repertoire of surface
markers, which allows its reproducible
and differential purification, (2) it is
selectively endowed of tumorigenic
capacity as opposed to all other
subsets, and (3) it sustains the growth
of heterogeneous cancer tissues,
which recreate the full repertoire of
cancer cell populations observed in
the parent tumor, thus displaying two
of the functional hallmarks of stem
cells: self-renewal and differentiation.
Based on these observations, the tu-
morigenic subset of cancer cells is
currently defined the ‘‘cancer stem
cell’’ (CSC) subset (Dalerba et al.,
2007).
Among the most ominous proper-
ties of malignant cancer cells is their
capacity to metastasize, i.e., to move
from their primary tissue of origin and
seed in a different anatomical com-
partment, where they sustain the
growth of a secondary tumor lesion.
Because CSC appear to be preferen-
tially endowed with the capacity toself-renew, and thus to be responsi-
ble for the long-term maintenance of
tumor growth, it has been predicted
that they might be also primarily
responsible for the formation of tu-
mor metastases (Dalerba et al.,
2007). This assumption, however, has
not yet been addressed experimen-
tally, and the relationship between
CSC and metastasis remains obscure.
In their present study, Hermann and
colleagues tried to shed light on this
fascinating research subject, using
human pancreatic cancer as a model
system (Hermann et al., 2007).
To characterize pancreatic CSC, the
authors analyzed fresh human primary
tumor tissues and showed that, in
some patients, the capacity to form
tumors after orthotopic injection in
the pancreas of immunodeficient
‘‘nude’’ mice was restricted to aminor-
ity population of CD133+ cells. Next,
the authors used a human pancreatic
cancer cell line and showed that the
CD133+ population of this cell line
could be further subdivided into two
subsets based on the expression of
the CXCR4 molecule (CD133+/
CXCR4neg and CD133+/CXCR4+).
Comparison of the tumorigenic capac-
ity of bulk CD133+ cells (containing
a mixture of CD133+/CXCR4neg and
CD133+/CXCR4+ cells) and of
CD133+ cells depleted of the CXCR4+
subset (i.e., CD133+/CXCR4neg)
showed that both populations were
equally capable to sustain tumor
growth. Interestingly, however, deple-
tion of the CXCR4+ subset from bulk
CD133+ cells was able to abrogate
the capacity of resulting tumors to
form spontaneous metastases, at
least in the short/medium term. ACell Stem Cell 1,similar effect was obtained by pharma-
cological inhibition of CXCR4.
These observations have impor-
tant implications, as they indicate that
targeting of CXCR4 might be key to
interfering with the spread of some
pancreatic tumors. CXCR4 is the
receptor for the CXCL12/SDF-1 che-
mokine and is involved in the control
of leukocyte trafficking. There is ample
evidence that CXCR4 can be directly
expressed by cancer cells and regu-
lates their migratory and metastatic
properties (Balkwill, 2004; Muller
et al., 2001). The present study, for
the first time, demonstrates the role
of CXCR4 in tumor metastasis by
using a model where multiple pheno-
typic cancer cell subpopulations coex-
ist in a dynamic equilibrium and where
the tumorigenic and metastatic prop-
erties of distinct cell subsets, including
CSC, can be tested independently,
trying to chart their functional and hier-
archical relationships.
Different models can be envisioned
to explain for the observations of
Hermann and colleagues (Hermann
et al., 2007) (Figure 1). It is possible
that two distinct subsets of CSC may
coexist in the same cancer cell popula-
tion: one with the capacity to self-
renew (CXCR4neg) and one with the
capacity to self-renew and form
metastases (CXCR4+). To test this
hypothesis, it will be necessary to
test the tumorigenic capacity of puri-
fied CXCR4+ cancer cells alone. If the
CXCR4+ subset proves to be tumori-
genic, a second question would arise:
what is the origin of CXCR4+ cancer
cells? Do they represent a distinct
genetic subclone of CSC that arose
as a result of additional DNAmutationsSeptember 2007 ª2007 Elsevier Inc. 241
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mutations that initiated the tumor
(Figure 1A)? Or do they represent
a CSC subset where induction of
CXCR4 expression results from ex-
posure to microenvironment stimuli
(Figure 1B)? To distinguish between
these possibilities, it will be necessary
to analyze tumors originated from
purified CXCR4neg and CXCR4+ can-
cer cells and evaluate whether or not
they contain mixtures of CXCR4neg
and CXCR4+ cells. It is also possible
that CXCR4+ cancer cells might be
devoid of tumorigenic capacity but
be endowed with a ‘‘facilitating’’ effect
on the formation of metastases, a role
somewhat similar to that of macro-
phages in many tumor model systems
(Figure 1C) (Balkwill and Mantovani,
2001; Coussens and Werb, 2001).
The answer to these questions, as
well as the definition of the relative
contribution of CXCR4 and other path-
ways in pancreatic cancer metastasis,
awaits a more comprehensive analysis
of pancreatic CSC isolated from multi-
ple patients’ fresh primary tissues.
Independently of the mechanisms
underlying the prometastatic effect
Figure 1. Possible Models to Explain the Origin of Metastasis-Promoting CXCR4+
Cancer Cells
Three alternative models can be envisioned to explain the origin of CXCR4+ cancer cells. In a first
scenario (A), CXCR4+ cancer cells might represent a genetic subclone of CSC, originated by
accumulation of additional genetic mutations. In this case, CXCR4+ cancer cells would retain
the tumorigenic potential of CSC but would be unable to give rise to CXCR4neg CSC subsets. A
second possibility (B) is that CXCR4+ cancer cells represent a reversible functional status of
CXCR4neg CSC. In this case, CXCR4+ cancer cells would display both tumorigenic potential
and the capacity to give rise to CXCR4neg CSC subsets. A third theoretical scenario (C) envisions
CXCR4+ cancer cells as bystander players, unable to self-renew and sustain tumor growth
by themselves but capable to promote metastatic dissemination, with a role similar to that of
macrophages in several tumor model systems.242 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.of CXCR4+ cancer cells, the observa-
tions reported by Hermann and col-
leagues (Hermann et al., 2007) have
interesting therapeutic implications,
as they point to possible approaches
to interfere with the metastatic
capacity of malignant pancreatic tu-
mors in vivo. Among them, one could
list the pharmacological inhibition of
the CXCR4 molecule (e.g., using
small synthetic compounds, some of
which already underwent phase I-II
trials in human subjects) or the in
vivo depletion of CXCR4+ cancer
cells (e.g., using anti-CXCR4 mono-
clonal antibodies). These approaches
would not be designed to kill CSC or
interfere with their growth but to
block their dissemination. In the natu-
ral history of most human cancers,
patients frequently undergo success-
ful surgical resection of primary
tumors but ultimately succumb to
distant site metastases that develop
later on. The possibility to ‘‘paralyze’’
tumors in a specific clinical stage
could represent a significant addition
to the oncologist’s weaponry and
gain time for patients with localized
disease.
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